KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Revenue (2016 - 2025)

Novavax (NVAX) has 16 years of Revenue data on record, last reported at $147.1 million in Q4 2025.

  • For Q4 2025, Revenue rose 66.61% year-over-year to $147.1 million; the TTM value through Dec 2025 reached $1.1 billion, up 55.28%, while the annual FY2025 figure was $1.1 billion, 64.69% up from the prior year.
  • Revenue reached $147.1 million in Q4 2025 per NVAX's latest filing, up from $70.4 million in the prior quarter.
  • Across five years, Revenue topped out at $734.6 million in Q3 2022 and bottomed at $70.4 million in Q3 2025.
  • Average Revenue over 5 years is $292.7 million, with a median of $204.6 million recorded in 2021.
  • Peak YoY movement for Revenue: surged 13143.38% in 2021, then tumbled 88.5% in 2023.
  • A 5-year view of Revenue shows it stood at $222.2 million in 2021, then skyrocketed by 60.85% to $357.4 million in 2022, then fell by 18.48% to $291.3 million in 2023, then tumbled by 69.69% to $88.3 million in 2024, then surged by 66.61% to $147.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $147.1 million in Q4 2025, $70.4 million in Q3 2025, and $175.0 million in Q2 2025.